alpelisib
Selected indexed studies
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. (N Engl J Med, 2019) [PMID:31091374]
- Alpelisib. (, 2012) [PMID:34633783]
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. (Ann Oncol, 2021) [PMID:33246021]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. (2021) pubmed
- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. (2019) pubmed
- Alpelisib. (2012) pubmed
- Alpelisib. (2006) pubmed
- Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). (2023) pubmed
- Alpelisib: First Global Approval. (2019) pubmed
- Alpelisib to treat breast cancer. (2020) pubmed
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. (2024) pubmed
- Pharmacokinetics and Pharmacodynamic of Alpelisib. (2023) pubmed
- Alpelisib for breast cancer. (2022) pubmed